Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
150.56
-3.76 (-2.44%)
At close: Sep 18, 2026, 4:00 PM EDT
150.70
+0.14 (0.09%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 29 employees as of December 31, 2025. The number of employees increased by 15 or 107.14% compared to the previous year.
Employees
29
Change (1Y)
15
Growth (1Y)
107.14%
Revenue / Employee
n/a
Profits / Employee
-$2,127,448
Market Cap
2.17B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 15 | 107.14% |
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Recursion Pharmaceuticals | 600 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Biohaven | 274 |
| Zenas BioPharma | 167 |
| Aurinia Pharmaceuticals | 128 |
PVLA News
- 4 days ago - Palvella Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 9 days ago - Palvella Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 10 days ago - Palvella Therapeutics Appoints James R. Treat, M.D. - GlobeNewsWire
- 17 days ago - Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 19 days ago - Palvella Therapeutics completes rolling submission of Qtorin NDA to FDA - TheFly
- 19 days ago - Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - GlobeNewsWire
- 5 weeks ago - Palvella Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 6 weeks ago - Palvella Therapeutics price target lowered to $207 from $210 at Truist - TheFly